DR5-targeting ADC / BlissBio - LARVOL DELTA

A DR5-targeting ADC exhibits superior anti-tumor activity and potentially better therapeutic window (AACR 2026) - "Later in a study of advanced Ewing sarcoma, Ozekibart combined with irinotecan and temozolomide demonstrated improved clinical benefit with an ORR of 64% and a DCR of 92%. Finally, this ADC showed better in vivo safety profile: lower on-target off-tumor apoptosis, longer half-life and better tolerability in comparison with that of INBRX109,suggesting a potentially wider therapeutic window. These results may support progression of this novel DR5-tageting ADC into clinical development as a potentially more potent and safer DR5-targeted therapy."

ADC • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor